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Neonatal diabetes occurs due to a genetic form of pan-
creatic bcell dysfunction. Mutations in a number of
genes have been identified in the last decade which has
helped not only in the etiological diagnosis but has also
influenced medical therapy.
Our proband was born at term with a birth weight of
3.99kg with no antenatal risk factors. He presented in
severe diabetic ketoacidosis at 8 weeks which required
intensive management. He was commenced on continu-
ous subcutaneous insulin infusion for his ongoing man-
agement. His initial genetic analysis for ABCC8, KCNJ11,
INS gene mutations was negative.
He demonstrated excellent glycaemic control with an
average HbA1C of 6.5% at 2 years of age. His growth and
development are appropriate for age with no associated
co-morbidities. However, further targeted next generation
sequencing of all known neonatal diabetes genes identified
a hemizygous FOXP3 missense mutation p.R347H with
his mother as a carrier. FOXP3 mutations cause IPEX syn-
drome, (immunodysregulation, polyendocrinopathy,
enteropathy, X-linked syndrome) and can be lethal in
infancy and early childhood. Prophylactic bone marrow
treatment is the only known cure for this condition.
Our proband has isolated neonatal diabetes with no
other features of IPEX. His maternal grandfather aged
63 years, was also hemizygous for the mutation. He had
enteropathy secondary to ulcerative colitis since child-
hood which was resistant to conventional treatment and
required colostomy. This makes him the oldest living
man with IPEX. Our proband’s maternal cousin also
had eczema in infancy which has resolved.
This case highlights the impact of genetic diagnosis on
the management of neonatal diabetes. A lethal condition
with no cure other than bone marrow transplant has now
been shown to have atypical manifestations with the avail-
ability of genetic testing. The management in our patient
is challenging given the poor genotype – phenotype corre-
lation and the dearth of information regarding milder
forms limited to a few case reports with similar mutation.
We have decided against prophylactic bone marrow trans-
plant and will consider it in the event of enteropathy or
another autoimmune manifestation.
Written informed Consent for this patient has been
taken including results of the genetic analyses according
to the Institutional Ethics Committee procedures of our
health service.
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